Trillium Therapeutics Inc (TRIL)

[NY1972]

CC-90002 – exploring optimization of CD47 target promise: Dr. Daniel pointed to preclinical data for this ph.I anti-CD47 antibody demonstrating some of the best tumor responses they have seen, and the company seems determined to capitalize on the congruence of its macrophage-related mechanism to more traditional T-cell IO approaches. It does seem like some additional work is still to be done; while they seemed confident the antibody construct would avoid hemagglutination, a side effect we note has been limiting for the target, they did highlight the need for continued ph.I work to better understand the complexity within tissue distribution and pharmacologic effect (in particular the thrombospondin ligand for the target), as well as the immune mechanism. AML seems to be the initial path forward, with the company submitting a plan to the FDA for this indication, and the company seemed determined to tackle some of the fundamental challenges with ‘90002 or follow-on antibodies.

http://www.investorvillage.com/smbd.asp?mb=341&mn=201733&pt=msg&mid=15519402